Royalty Pharma stock price target raised to $38 from $37 at UBS
PositiveFinancial Markets

UBS has raised its price target for Royalty Pharma's stock from $37 to $38, indicating a positive outlook for the company.
Editor’s Note: This adjustment in the price target reflects UBS's confidence in Royalty Pharma's performance, which could influence investor sentiment and market dynamics.
— Curated by the World Pulse Now AI Editorial System